Compare ADPT & POR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADPT | POR |
|---|---|---|
| Founded | 2009 | 1889 |
| Country | United States | United States |
| Employees | N/A | 2915 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 5.5B |
| IPO Year | 2019 | 1994 |
| Metric | ADPT | POR |
|---|---|---|
| Price | $27.73 | $45.29 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 12 |
| Target Price | $33.86 | ★ $50.90 |
| AVG Volume (30 Days) | ★ 2.1M | 1.9M |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 4.86% |
| EPS Growth | ★ 63.89 | N/A |
| EPS | N/A | ★ 1.98 |
| Revenue | $276,976,000.00 | ★ $3,576,000,000.00 |
| Revenue This Year | $10.85 | $2.75 |
| Revenue Next Year | $21.60 | $7.41 |
| P/E Ratio | ★ N/A | $22.92 |
| Revenue Growth | ★ 54.77 | 3.95 |
| 52 Week Low | $12.00 | $43.26 |
| 52 Week High | $32.21 | $54.62 |
| Indicator | ADPT | POR |
|---|---|---|
| Relative Strength Index (RSI) | 49.06 | 48.18 |
| Support Level | $24.02 | $43.29 |
| Resistance Level | $29.92 | $45.72 |
| Average True Range (ATR) | 1.71 | 0.77 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 31.91 | 24.49 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two-thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.6 gigawatts of gas, coal, wind, and hydro generation, along with 300 megawatts of energy storage. In February 2026, PGE proposed acquiring utilities in Washington state from Berkshire Hathaway Energy.